Trade Cyclerion Therapeutics, Inc. - CYCN CFD

Add to favourite

3.1414

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.3572

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.01

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Cyclerion Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	3.1414
Open*	3.1414
1-Year Change*	1048.17%
Day's Range*	3.1414 - 3.1414
52 wk Range	1.75-19.14
Average Volume (10 days)	5,140.00
Average Volume (3 months)	164.01K
Market Cap	8.80M
P/E Ratio	-100.00K
Shares Outstanding	2.45M
Revenue	608.00K
EPS	-7.85
Dividend (Yield %)	N/A
Beta	1.77
Next Earnings Date	Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	3.1414	0.0000	0.00%	3.1414	3.1414	3.1414
Apr 17, 2024	3.1414	0.0000	0.00%	3.1414	3.1414	3.1014
Apr 16, 2024	3.1414	-0.0300	-0.95%	3.1714	3.1714	3.1414
Apr 15, 2024	3.1414	-0.2200	-6.54%	3.3614	3.3614	3.1314
Apr 12, 2024	3.3514	0.3600	12.03%	2.9914	3.4914	2.9914
Apr 11, 2024	2.8914	0.1800	6.64%	2.7114	2.8914	2.6414
Apr 10, 2024	2.7914	-0.0800	-2.79%	2.8714	2.9414	2.7914
Apr 9, 2024	3.1514	0.1800	6.06%	2.9714	3.2114	2.9014
Apr 8, 2024	3.0414	0.0500	1.67%	2.9914	3.0714	2.8214
Apr 5, 2024	3.0414	0.0400	1.33%	3.0014	3.0914	2.9914
Apr 4, 2024	3.0514	-0.3200	-9.49%	3.3714	3.8714	3.0514
Apr 2, 2024	3.0514	0.0600	2.01%	2.9914	3.0914	2.9914
Apr 1, 2024	3.0514	0.0800	2.69%	2.9714	3.0514	2.9014
Mar 28, 2024	3.1914	0.0000	0.00%	3.1914	3.2914	3.1914
Mar 27, 2024	2.9914	0.0800	2.75%	2.9114	2.9914	2.9114
Mar 26, 2024	2.9914	0.0000	0.00%	2.9914	2.9914	2.9014
Mar 25, 2024	2.8914	-0.1000	-3.34%	2.9914	2.9914	2.8914
Mar 22, 2024	2.9914	0.0000	0.00%	2.9914	2.9914	2.9914
Mar 21, 2024	3.1414	0.1500	5.01%	2.9914	3.1914	2.9914
Mar 20, 2024	3.1414	0.2300	7.90%	2.9114	3.2614	2.8914

Cyclerion Therapeutics, Inc. Events

Time (UTC)	Country	Event
Thursday, May 9, 2024
Time (UTC) 20:00	Country US	Event Q1 2024 Cyclerion Therapeutics Inc Earnings Release Q1 2024 Cyclerion Therapeutics Inc Earnings Release Forecast - Previous -
Tuesday, May 14, 2024
Time (UTC) 12:00	Country US	Event Cyclerion Therapeutics Inc Annual Shareholders Meeting Cyclerion Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -
Friday, July 26, 2024
Time (UTC) 20:00	Country US	Event Q2 2024 Cyclerion Therapeutics Inc Earnings Release Q2 2024 Cyclerion Therapeutics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	1.625	3.942	2.296	4.507	0
Total Operating Expense	45.997	55.573	83.561	129.544	115.252
Selling/General/Admin. Expenses, Total	14.504	20.62	28.816	34.404	27.536
Research & Development	31.493	37.636	56.414	95.14	87.716
Operating Income	-44.372	-51.631	-81.265	-125.037	-115.252
Net Income Before Taxes	-44.078	-51.647	-77.802	-123.008	-115.252
Net Income After Taxes	-44.078	-51.647	-77.802	-123.008	-115.252
Net Income Before Extra. Items	-44.078	-51.647	-77.802	-123.008	-115.252
Net Income	-44.078	-51.647	-77.802	-123.008	-115.252
Income Available to Common Excl. Extra. Items	-44.078	-51.647	-77.802	-123.008	-115.252
Income Available to Common Incl. Extra. Items	-44.078	-51.647	-77.802	-123.008	-115.252
Diluted Net Income	-44.078	-51.647	-77.802	-123.008	-115.252
Diluted Weighted Average Shares	2.17345	1.9572	1.52015	1.369	1.37008
Diluted EPS Excluding Extraordinary Items	-20.2802	-26.3882	-51.1805	-89.8524	-84.1205
Dividends per Share - Common Stock Primary Issue					0
Diluted Normalized EPS	-20.2802	-27.759	-52.5415	-90.4368	-84.1205
Total Extraordinary Items					0
Revenue	1.625	3.942	2.296	4.507
Interest Income (Expense), Net Non-Operating	0.294	-0.016	0.588	2.029
Unusual Expense (Income)	0	-2.683	-1.669
Other, Net		0	2.875

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0.608	0	0.306
Revenue	0	0	0.608	0	0.306
Total Operating Expense	4.243	7.042	7.956	10.607	13.739
Selling/General/Admin. Expenses, Total	3.357	3.269	3.506	3.525	3.521
Research & Development	0.886	3.773	4.45	7.082	10.218
Unusual Expense (Income)			0	0	0
Operating Income	-4.243	-7.042	-7.348	-10.607	-13.433
Interest Income (Expense), Net Non-Operating	0.062	0.088	0.132	0.111	0.045
Net Income Before Taxes	-4.181	-6.954	-7.216	-10.496	-13.388
Net Income After Taxes	-4.181	-6.954	-7.216	-10.496	-13.388
Net Income Before Extra. Items	-4.181	-6.954	-7.216	-10.496	-13.388
Net Income	-4.181	-6.954	-7.216	-10.496	-13.388
Income Available to Common Excl. Extra. Items	-4.181	-6.954	-7.216	-10.496	-13.388
Income Available to Common Incl. Extra. Items	-4.181	-6.954	-7.216	-10.496	-13.388
Diluted Net Income	-4.181	-6.954	-7.216	-10.496	-13.388
Diluted Weighted Average Shares	2.282	2.17605	2.17525	2.1744	2.17295
Diluted EPS Excluding Extraordinary Items	-1.83216	-3.1957	-3.31732	-4.82708	-6.16121
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-1.83216	-3.1957	-3.31732	-4.82708	-6.16121

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	14.82	55.457	58.501	101.197	0.879
Prepaid Expenses	0.805	0.928	0.816	1.966	0.867
Other Current Assets, Total	0.537	0.468	3.163	2.862	0.012
Total Assets	18.079	59.331	115.378	186.478	7.401
Property/Plant/Equipment, Total - Net	1.218	1.467	50.267	79.75	6.497
Property/Plant/Equipment, Total - Gross	3.399	3.667	60.554	101.352	21.988
Accumulated Depreciation, Total	-2.181	-2.2	-10.287	-21.602	-15.491
Other Long Term Assets, Total	2.041	2.407	6.61	5.531	0.025
Total Current Liabilities	7.627	11.085	16.952	18.249	17.846
Accounts Payable	2.97	1.828	1.435	3.311	2.781
Accrued Expenses	4.589	8.759	11.832	14.534	14.295
Notes Payable/Short Term Debt	0	0	3.509	0	0
Other Current Liabilities, Total	0.068	0.498	0.176	0.404	0.77
Total Liabilities	7.627	11.085	55.885	88.749	17.846
Total Long Term Debt	0	0	0	0	0
Total Equity	10.452	48.246	59.493	97.729	-10.445
Other Equity, Total	-0.02	-0.023	-0.027	-0.02	-10.445
Total Liabilities & Shareholders’ Equity	18.079	59.331	115.378	186.478	7.401
Total Common Shares Outstanding	2.17594	2.17051	1.70237	1.37991	1.37008
Cash and Short Term Investments	13.382	53.961	54.395	94.895
Cash & Equivalents	13.382	53.961	54.395	94.895
Total Receivables, Net	0.096	0.1	0.127	1.474
Accounts Receivable - Trade, Net	0.096	0.1	0.127	1.474
Other Liabilities, Total	0	0	38.933	70.5
Common Stock	0	0	0	0
Additional Paid-In Capital	269.626	263.345	222.949	183.376
Retained Earnings (Accumulated Deficit)	-259.154	-215.076	-163.429	-85.627

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	9.864	7.113	8.335	14.82	21.656
Cash and Short Term Investments	9.108	5.641	7.169	13.382	20.405
Cash & Equivalents	9.108	5.641	7.169	13.382	20.405
Total Receivables, Net	0	0	0.096	0.096	0.227
Accounts Receivable - Trade, Net	0	0	0.096	0.096	0.227
Prepaid Expenses	0.726	1.044	0.567	0.805	0.536
Other Current Assets, Total	0.03	0.428	0.503	0.537	0.488
Total Assets	15.214	10.097	11.456	18.079	25.053
Property/Plant/Equipment, Total - Net	0	1.125	1.171	1.218	1.264
Property/Plant/Equipment, Total - Gross	0.126	3.293	3.345	3.399	3.529
Accumulated Depreciation, Total	-0.126	-2.168	-2.174	-2.181	-2.265
Other Long Term Assets, Total	0	1.859	1.95	2.041	2.133
Total Current Liabilities	2.341	4.947	7.531	7.627	8.529
Accounts Payable	0.814	1.864	3.925	2.97	1.645
Accrued Expenses	1.369	1.973	3.466	4.589	6.725
Notes Payable/Short Term Debt	0	0	0	0	0
Other Current Liabilities, Total	0.158	1.11	0.14	0.068	0.159
Total Liabilities	2.341	4.947	7.531	7.627	8.529
Total Long Term Debt	0	0	0	0	0
Other Liabilities, Total		0	0	0	0
Total Equity	12.873	5.15	3.925	10.452	16.524
Common Stock		0	0	0	0
Additional Paid-In Capital	275.614	275.455	270.052	269.626	268.49
Retained Earnings (Accumulated Deficit)	-262.723	-270.289	-266.108	-259.154	-251.938
Other Equity, Total	-0.018	-0.016	-0.019	-0.02	-0.028
Total Liabilities & Shareholders’ Equity	15.214	10.097	11.456	18.079	25.053
Total Common Shares Outstanding	2.4451	2.4078	2.17624	2.17594	2.17471
Total Preferred Shares Outstanding	0.35104	0.35104
Long Term Investments	5.35

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-44.078	-51.647	-77.802	-123.008	-115.252
Cash From Operating Activities	-40.611	-36.517	-72.49	-102.215	-97.503
Cash From Operating Activities	0.065	0.472	2.297	2.7	1.528
Non-Cash Items	6.252	13.25	10.607	20.382	12.433
Changes in Working Capital	-2.85	1.408	-7.592	-2.289	3.788
Cash From Investing Activities	0	1.457	0.018	-6.715	-3.438
Capital Expenditures	0	-0.007	-1.524	-6.888	-3.438
Cash From Financing Activities	0.029	30.785	28.09	211.571	100.941
Financing Cash Flow Items				36.061	100.941
Net Change in Cash	-40.579	-4.271	-44.389	102.621	0
Other Investing Cash Flow Items, Total	0	1.464	1.542	0.173
Issuance (Retirement) of Stock, Net	0.029	30.785	24.581	175.51
Foreign Exchange Effects	0.003	0.004	-0.007	-0.02
Issuance (Retirement) of Debt, Net		0	3.509

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-6.954	-44.078	-36.862	-26.366	-12.978
Cash From Operating Activities	-6.214	-40.611	-33.568	-23.653	-12.835
Cash From Operating Activities	0	0.065	0.065	0.065	0.048
Non-Cash Items	0.426	6.252	5.128	3.466	1.767
Changes in Working Capital	0.314	-2.85	-1.899	-0.818	-1.672
Cash From Investing Activities		0	0	0	0
Capital Expenditures		0	0
Other Investing Cash Flow Items, Total		0	0	0	0
Cash From Financing Activities		0.029	0.017	0.017	0
Issuance (Retirement) of Stock, Net		0.029	0.017	0.017	0
Net Change in Cash	-6.213	-40.579	-33.556	-23.638	-12.836
Issuance (Retirement) of Debt, Net
Foreign Exchange Effects	0.001	0.003	-0.005	-0.002	-0.001

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cyclerion Therapeutics, Inc. Company profile

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cyclerion Therapeutics Inc revenues increased 72% to $3.9M. Net loss decreased 34% to $51.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 32% to $33.7M (expense), General & Administrative - Balancing decrease of 27% to $15M (expense).

Industry:

Biotechnology & Medical Research (NEC)

301 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024